For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Histological confirmation of renal cell carcinoma (RCC) with a clear cell component,
             including participants who may also have sarcomatoid features

          -  Advanced RCC (not amenable to curative surgery or radiation therapy) or metastatic RCC
             (Stage IV)

          -  Measurable disease as defined by Response Evaluation Criteria in Solid Tumor (RECIST)
             v1.1 criteria within 28 days prior to randomization

          -  Received no more than 2 prior systemic treatment regimens

          -  Intolerance or progression on or after the last treatment regimen received and within
             6 months prior to randomization on the study

          -  Karnofsky PS ≥ 70 at screening

          -  Must agree to follow specific methods of contraception, if applicable

        Exclusion Criteria:

          -  Untreated, symptomatic central nervous system (CNS) metastases

          -  Concurrent malignancy (present during screening) requiring treatment or history of
             prior malignancy active within 2 years prior to randomization

          -  Active, known, or suspected autoimmune disease

          -  Known human immunodeficiency virus (HIV) positive with an acquired immunodeficiency
             syndrome (AIDS) defining opportunistic infection within the last year, or a current
             CD4 count < 350 cells/μL. Participants with HIV are eligible if:

               1. They have received established antiretroviral therapy (ART) for at least 4 weeks
                  prior to randomization

               2. They continue on ART as clinically indicated while enrolled on study

               3. CD4 counts and viral load are monitored per standard of care by a local health
                  care provider

               4. Inclusion of participants with HIV should be based on Investigator clinical
                  judgment in consultation with the Medical Monitor NOTE: Testing for HIV must be
                  performed at sites where mandated locally. HIV-positive participants must be
                  excluded where mandated locally

          -  Serious or uncontrolled medical disorders including for example, active severe acute
             respiratory syndrome coronavirus 2 (SAR-CoV-2) infection within approximately 4 weeks
             prior to screening. In the case of prior SARS-CoV-2 infection, acute symptoms must
             have resolved based on investigator clinical judgment and, in consultation with
             Medical Monitor, there are no sequelae that would place the participant at a higher
             risk of receiving investigational treatment to be eligible

          -  Prior treatment with an programmed death receptor-1 (anti-PD-1), programmed death
             ligand-1 (anti-PD-L1), or cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4)
             antibody, or any other antibody or drug specifically targeting T-cell costimulation or
             checkpoint pathways

          -  Treatment with any live attenuated vaccine within 30 days of first study treatment

        Other protocol-defined inclusion/exclusion criteria apply